News

Cordance Medical and EXACT Therapeutics Announce Strategic Partnership to Revolutionize Drug Delivery to the Brain Cordance Medical, a leading innovator in non-invasive opening of the blood-brain barrier (BBB), and EXACT Therapeutics, a clinical-stage Norwegian biopharmaceutical precision health company developing Acoustic Cluster Therapy (ACT®), today announced a strategic partnership aimed at combining their breakthrough technologies to revolutionize drug delivery in the treatment of brain diseases. Cordance Medical’s NeuroAccess™ platform is designed […] September 7, 2023

Kiyatec Announces Investment from Leading Brain Cancer Venture Philanthropy Funds Leader in functional precision oncology received funding support from investment arms of the National Brain Tumor Society and the Sontag Foundation KIYATEC, Inc., the leader in functional precision oncology technology, today announced a new investment from the venture philanthropy arms of two leading brain tumor patient organizations. The Brain Tumor Investment Fund, a affiliate of […] May 18, 2023

Brain Tumor Investment Fund Names Managing Director  National Brain Tumor Society’s venture philanthropy affiliate appoints industry veteran to lead fund designed to invest in and accelerate development of promising new technologies for patients with brain cancer. Today, the Brain Tumor Investment Fund, an affiliate of the National Brain Tumor Society (NBTS), announced that it has named John Higgins, a 30-year veteran of […] April 25, 2023

Science Publication First to Describe Modifi Bio’s Novel Approach to Fight Cancer Cells with DNA Modification Yale Spinout Modifi Bio announces seed funding NEW HAVEN, Conn., July 28, 2022 (GLOBE NEWSWIRE) — Modifi Biosciences announced today that the journal Science has published a critical study validating the company’s novel oncology platform based on new classes of molecules that exploit tumor-associated DNA repair defects through direct cancer cell DNA modification. The company closed a $6.4M seed […] August 1, 2022

FDA Grants Alpheus Medical Orphan Drug and Fast Track Designations for Novel Sonodynamic Therapy for Brain Cancer The company is currently enrolling patients in a multi-center Phase 1 clinical trial for the treatment of recurrent glioblastoma (GBM) OAKDALE, Minn., July 13, 2022  /PRNewswire/ — Alpheus™ Medical, Inc, a privately held company developing a novel sonodynamic therapy (SDT) platform targeting solid body cancers, today announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug […] July 13, 2022